A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes
A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
The primary objective is to determine if LY2382770, administered monthly for 1 year, is more effective than placebo at slowing the progression of diabetic kidney disease in participants treated with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB).
Main Inclusion Criteria:
Main Exclusion Criteria:
Female participants who can become pregnant, are pregnant or breastfeeding
Participants who have any of the following medical conditions (the site research staff will discuss these criteria and determine a participant's ability to participate)
Phoenix, Arizona 85012, United States
Inglewood, California 90301, United States
Los Angeles, California 90073, United States
Northridge, California 91324, United States
Denver, Colorado 80220, United States
Port Charlotte, Florida 33952, United States
Tampa, Florida 33614, United States
Atlanta, Georgia 30342, United States
Idaho Falls, Idaho 83404, United States
Wichita, Kansas 67214, United States
Kenner, Louisiana 70065, United States
Rockville, Maryland 20852, United States
Kansas City, Missouri 64128, United States
Omaha, Nebraska 68131, United States
Chapel Hill, North Carolina 27599, United States
Charlotte, North Carolina 28207, United States
Durham, North Carolina 27705, United States
Greenville, North Carolina 27834, United States
Winston-Salem, North Carolina 27157, United States
Beachwood, Ohio 44122, United States
Bend, Oregon 97701, United States
Providence, Rhode Island 02903, United States
Orangeburg, South Carolina 29118, United States
Dallas, Texas 75390, United States
Lufkin, Texas 75904, United States
St. George, Utah 84770, United States
Suffolk, Virginia 23435, United States
Milwaukee, Wisconsin 53295, United States
Camperdown, New South Wales 2050, Australia
Concord, New South Wales 2139, Australia
Gosford, New South Wales 2250, Australia
Liverpool, New South Wales 2170, Australia
Adelaide, South Australia 5000, Australia
Launceston, Tasmania 7250, Australia
Box Hill, Victoria 3128, Australia
Fitzroy, Victoria 3065, Australia
Heidelberg, Victoria 3084, Australia
Melbourne, Victoria 3004, Australia
Parkville, Victoria 3050, Australia
Reservoir, Victoria 3073, Australia
Nedlands, Western Australia 6009, Australia
Český Krumlov, 381 27, Czechia
Děčín, 405 99, Czechia
Jilemnice, 514 15, Czechia
Liberec, 460 63, Czechia
Ostrava, 703 84, Czechia
Prague, 181 02, Czechia
Tábor, 390 02, Czechia
Teplice, 415 01, Czechia
Grenoble, 38043, France
Lyon, 69437, France
Nanterre, 92014, France
Valenciennes, 59322, France
Vandœuvre-lès-Nancy, 54511, France
Baja, 6500, Hungary
Balatonfüred, 8230, Hungary
Budapest, 1096, Hungary
Gyöngyös, 3200, Hungary
Győr, 9023, Hungary
Kaposvár, 7400, Hungary
Nagykanizsa, 8800, Hungary
Szeged, 6720, Hungary
Szigetvár, 7900, Hungary
Zalaegerszeg, 8900, Hungary
Ashkelon, 78278, Israel
Hadera, 38100, Israel
Haifa, 31096, Israel
Holon, 58100, Israel
Jerusalem, 91120, Israel
Kfar Saba, 44281, Israel
Nahariya, 22100, Israel
Rehovot, 76100, Israel
Safed, 13110, Israel
Tel Aviv, 64239, Israel
Tel Litwinsky, 52621, Israel
Ẕerifin, 70300, Israel
Cidra, 00739, Puerto Rico